A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men

Objective: The study aimed to explore the bioequivalence of a proposed biosimilar BAT1806 to its reference products marketed in the EU and US (RoActemra-EU and Actemra-US) among healthy Chinese men. The tolerance, immunogenicity, and pharmacokinetics (PK) of the three drugs were also investigated. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hong, Wang, Hong, Wei, Haijing, Chen, Hong, Liu, Jingrui, Li, Cuiyun, Zhu, Xiaoxue, Li, Xiaojiao, Yu, Jinchen, Zhou, Yinbo, Yang, Xiaolei, Wang, Zhaohe, Wu, Min, Ding, Yanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868548/
https://www.ncbi.nlm.nih.gov/pubmed/33569002
http://dx.doi.org/10.3389/fphar.2020.609522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868548/
https://www.ncbi.nlm.nih.gov/pubmed/33569002
http://dx.doi.org/10.3389/fphar.2020.609522

Ejemplares similares